title: Efficiency of HAART in the prevention of mother to children HIV-1 transmission at Saint Camille medical centre in Burkina Faso, West Africa.
abstract: OBJECTIVE
  To evaluate efficiency of HAART in the prevention of mother to child HIV transmission.
  
  
  METHODS
  A longitudinal study was conducted on 1 300 women attending the antenatal service at Saint Camille Medical Centre from September 2010 to July 2011. The HIV status of mothers was determined by rapid tests and ELISA. Discordant results were confirmed by real-time PCR. PCR was used to determine HIV status of children born from HIV-positive mothers.
  
  
  RESULTS
  Among 1 300 pregnant women tested for HIV, 378 were seropositive. Mothers were predominantly housewives (69.7%), and their mean age was (28.32±0.15) years. The overall prevalence of HIV transmission from mother to child was 4.8% (18/378). This prevalence differed significantly from 0.0% (0/114) to 6.8% (18/264) in children born from mothers under HAART and those with mothers under New Prophylactic Protocol (AZT + 3TC + NVP), respectively (P< 0.01). Children's mortality rate during the medical follow up was 1.3% (5/378). Among 16 women with HIV dubious status by ELISA, the Real Time PCR confirmed 2/16 (12.5%) as HIV positive.
  
  
  CONCLUSIONS
  The protocol of prevention of mother to children HIV transmission (PMTCT) is effective. The rate of HIV vertical transmission is significantly reduced. Early diagnosis determined by PCR of children born from HIV-positive mother is necessary and recommended in the context of PMTCT in Burkina Faso. We also found that PCR is an effective tool to confirm HIV status in pregnant women.
authors.affiliation: Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, UFR/SVT, Université de Ouagadougou, Burkina Faso.
authors.forename: Laure Stella Ghoma
authors.initials: LS
authors.lastname: Linguissi
authors.forename: Cyrille
authors.initials: C
authors.lastname: Bisseye
authors.forename: Tani
authors.initials: T
authors.lastname: Sagna
authors.forename: Bolni Marius
authors.initials: BM
authors.lastname: Nagalo
authors.forename: Djeneba
authors.initials: D
authors.lastname: Ouermi
authors.forename: Florencia W
authors.initials: FW
authors.lastname: Djigma
authors.forename: Salvatore
authors.initials: S
authors.lastname: Pignatelli
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Sia
authors.forename: Virginio
authors.initials: V
authors.lastname: Pietra
authors.forename: Remy
authors.initials: R
authors.lastname: Moret
authors.forename: Jean Baptiste
authors.initials: JB
authors.lastname: Nikiema
authors.forename: Jacques
authors.initials: J
authors.lastname: Simpore
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002050:Burkina Faso / Q000453:epidemiology; D002648:Child; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D015995:Prevalence; D011446:Prospective Studies; D012959:Socioeconomic Factors
chemical_list: D019380:Anti-HIV Agents